Synthetic 28-amino-acid thymic immunomodulatory peptide
Thymosin Alpha-1 is an immune-modulating peptide studied in serious infections, chronic viral hepatitis, and as an add-on to cancer treatment. It has real human-trial history, but results are mixed: the largest modern Phase 3 trial found no sepsis-mortality benefit, and broad immune-boosting or wellness claims have not been demonstrated.
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Research at a glance
Depth and confidence summarize the research record—not effectiveness, safety, or a recommendation.
Controlled Phase 2 and Phase 3 studies span sepsis, hepatitis B, COVID-19, and oncology, alongside human pharmacokinetic research.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Large and disease-specific trials have produced neutral, borderline, or subgroup-dependent findings rather than a consistent general immune benefit.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not a suggested amount.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: These regimens belong to specific diseases, products, combinations, and monitored protocols. They are not interchangeable starter amounts or evidence that TA1 broadly 'boosts' immunity, and no FDA-approved U.S. TA1 product was identified. Amounts shown describe cited research exposure—not a dosage recommendation.
Practical starting point
Common goals and questions—not recommendations or promises of benefit.
The overview, studies, and source ledger below explain what supports each label—and where the evidence stops.
What the evidence says
The 1,106-participant, double-blind, placebo-controlled Phase 3 TESTS sepsis trial—which found no reduction in 28-day mortality.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Whether any biomarker-defined subgroup has reproducible benefit, the safety and value of long-term or repeated use, and whether broad wellness claims translate into meaningful clinical outcomes.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
The evidence story
Importance shows how much an item changes the evidence story. Quality shows how much confidence the design deserves. A strong negative study can score highly on both.
Importance and quality answer different questions. A rigorous study can be highly important even when it challenges a popular claim.
Among 1,089 participants in the modified intention-to-treat analysis, 28-day mortality was 23.4% with TA1 and 24.1% with placebo. No secondary or safety outcome differed significantly.
The study reported lower mortality in the severe subgroup with TA1 than placebo. Sixty-seven adverse events occurred in 42 participants, including eight serious events that were deaths.
No results were posted by the July 25, 2026 evidence cutoff.
TA1-containing groups showed numerically longer survival and progression-free survival, but reported comparisons did not reach conventional statistical significance. TA1 did not add measurable toxicity.
TA1 influenced dendritic-cell signaling through TLR9 and type-I-interferon pathways and produced both inflammatory-resistance and regulatory-tolerance signals.
Administration and handling
The Phase 3 sepsis trial used a monitored protocol of 1.6 mg subcutaneous TA1 every 12 hours for seven days. The chronic-hepatitis-B Phase 3 trial used 1.6 mg subcutaneously twice weekly for six months. A nine-person pharmacokinetic study used 900 micrograms per square meter subcutaneously. These are descriptions of specific research protocols—not recommended doses, starter doses, cycles, escalation schedules, or support for self-treatment.
No FDA-approved TA1 product label or regulator-validated consumer reconstitution and storage standard was identified. Research formulations, internationally marketed products, compounded preparations, and seller-supplied powders cannot be assumed interchangeable. FDA cites peptide-related impurities, API-characterization complexity, possible immunogenicity for certain routes, and inadequate safety information for compounded TA1.
Primary-source ledger
2025-01-15 · PMID 39814420 · NCT02867267 · DOI 10.1136/bmj-2024-082583
2022-08-01 · PMID 36042753 · DOI 10.5005/jp-journals-10071-24298
2021-10-22 · NCT05086614
2010-05-01 · PMID 20194853 · DOI 10.1093/annonc/mdp520
2006-10-01 · PMID 16741252 · DOI 10.1182/blood-2006-02-004762
1999-12-01 · PMID 10607256
1999-01-01 · PMID 10027483